About
0.80USD-0.07 -7.58%
Closed • Updated at 18:04 GMT+00:00Market Cap$11.86M
Volume14.43M
Beta-2.41
RSI60.48
Soligenix, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 26 2026
Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo
May 8 2026
Soligenix Announces Recent Updates and First Quarter 2026 Financial Results
Apr 28 2026
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
Apr 2 2026
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
Mar 31 2026
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
Recent Videos

SNGX Stock Analysis | Soligenix, Inc. Stock Latest Chart Update
May 27, 2026

Innovative Drug Development in Dermatology and Glioblastoma Treatment
Apr 14, 2026

RedChip DealFlow Special: 4 Small-Cap CEO Interviews | SNGX, AIDX, SOPA, BKYI
Apr 11, 2026

Soligenix: Advancing HyBryte™ Toward Commercialization & Expanding Biotech Pipeline
Mar 31, 2026
Community Chat
Ask AI
Try asking
Translate